Communiqués Turn Therapeutics Inc.

Actions

TTRX

US90021W1053

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
12,00 ^USD	+5,36%		-9,98%	+204,57%

09/09	Turn Therapeutics Inc. annonce la nomination de Robert R. Redfield au poste de directeur scientifique	CI
20/08	Turn Therapeutics annonce une étude évaluée par les pairs démontrant que le GX-03 réduit sélectivement les principaux vecteurs de l'inflammation cutanée et des démangeaisons	CI

Communiqués

10/09	Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum	BU
09/09	Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer	BU
20/08	Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch	BU
12/08	Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results	BU
28/07	Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026	BU
07/07	Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis	BU
06/07	Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis	BU
01/06	Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis	BU
27/05	Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model	BU
19/05	Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026	BU
18/05	Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead	BU
11/05	Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates	BU
31/03	Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates	BU
24/03	Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group	BU
17/02	Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs	BU
09/02	Turn Therapeutics : Corporate Presentation	PU
09/02	Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences	BU
12/01	Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference	BU
07/01	Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors	GL
07/01	Turn Therapeutics : Corporate Presentation	PU
13/11	Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates	GL
12/11	Turn Therapeutics GX-03 Technology Named as One of Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment by Patient Care Online Magazine	AQ
11/11	Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.	GL
11/11	Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine	GL
04/11	Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications	GL